Literature DB >> 25801713

Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.

Konstantin Golovine1, Peter Makhov, Sei Naito, Henish Raiyani, Jeffrey Tomaszewski, Reza Mehrazin, Alexei Tulin, Alexander Kutikov, Robert G Uzzo, Vladimir M Kolenko.   

Abstract

The c-Met protein, a transmembrane receptor tyrosine kinase, is the product of a proto-oncogene. Its only known ligand, hepatocyte growth factor (HGF), regulates cell growth, motility, migration, invasion, proliferation, and angiogenesis. The aberrant expression of c-Met is often associated with poor prognosis in multiple cancers, including renal cell carcinoma (RCC). Silencing or inactivation of c-Met leads to decreased viability of cancer cells, thereby making ablation of c-Met signaling an attractive concept for developing novel strategies for the treatment of renal tumors. Naturally-occurring products or substances are the most consistent source of drug development. As such, we investigated the functional impact of piperlongumine (PL), a naturally occurring alkaloid present in the Long pepper (Piper longum) on c-Met expression in RCC cells and demonstrated that PL and its analogs rapidly reduce c-Met protein and RNA levels in RCC cells via ROS-dependent mechanism. PL-mediated c-Met depletion coincided with the inhibition of downstream c-Met signaling; namely Erk/MAPK, STAT3, NF-κB and Akt/mTOR. As such, PL and PL analogs hold promise as potential therapeutic agents for the treatment of metastatic RCC and the prevention of postoperative RCC recurrence.

Entities:  

Keywords:  Erk, Extracellular signal-regulated kinase; FAK, Focal adhesion kinase; HGF, Hepatocyte growth factor; MAPK, Mitogen-activated protein kinase; NF-kB, Nuclear factor kappaB; PL, Piperlongumine; PL-Di, PL-Dimer; PL-FPh, PL-fluorophenyl; RCC, Renal cell carcinoma; RECIST, Response evaluation criteria in solid tumors; RNA, Ribonucleic acid; ROS; ROS, Reactive oxygen species; STAT, Signal transducer and activator of transcription; TKIs, Tyrosine kinase inhibitors; VEGFR, Vascular endothelial growth factor receptor; c-Met; cancer; mTOR, Mammalian target of rapamycin; piperlongumine; renal

Mesh:

Substances:

Year:  2015        PMID: 25801713      PMCID: PMC4623021          DOI: 10.1080/15384047.2015.1026511

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  40 in total

1.  New amides and gastroprotective constituents from the fruit of Piper chaba.

Authors:  Toshio Morikawa; Hisashi Matsuda; Itadaki Yamaguchi; Yutana Pongpiriyadacha; Masayuki Yoshikawa
Journal:  Planta Med       Date:  2004-02       Impact factor: 3.352

Review 2.  The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Authors:  Daniel Cho; Sabina Signoretti; Meredith Regan; James W Mier; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Authors:  Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 4.  New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.

Authors:  Brian I Rini
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 5.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

Review 6.  Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.

Authors:  Lauren C Harshman; Toni K Choueiri
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

Review 7.  MET: a critical player in tumorigenesis and therapeutic target.

Authors:  Carrie R Graveel; David Tolbert; George F Vande Woude
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

Review 8.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 9.  ROS stress in cancer cells and therapeutic implications.

Authors:  Helene Pelicano; Dennis Carney; Peng Huang
Journal:  Drug Resist Updat       Date:  2004-04       Impact factor: 18.500

10.  Reactive oxygen species: role in the development of cancer and various chronic conditions.

Authors:  Gulam Waris; Haseeb Ahsan
Journal:  J Carcinog       Date:  2006-05-11
View more
  14 in total

1.  Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo.

Authors:  Chaoqin Duan; Bin Zhang; Chao Deng; Yu Cao; Fan Zhou; Longyun Wu; Min Chen; Shanshan Shen; Guifang Xu; Shu Zhang; Guihua Duan; Hongli Yan; Xiaoping Zou
Journal:  Tumour Biol       Date:  2016-02-13

2.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

Review 3.  Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms.

Authors:  Essa M Bajalia; Farah B Azzouz; Danielle A Chism; Derrek M Giansiracusa; Carina G Wong; Kristina N Plaskett; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

4.  Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.

Authors:  Yingying Wang; Jianhui Chang; Xingui Liu; Xuan Zhang; Suping Zhang; Xin Zhang; Daohong Zhou; Guangrong Zheng
Journal:  Aging (Albany NY)       Date:  2016-11-19       Impact factor: 5.682

Review 5.  A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis.

Authors:  Yasuyoshi Miyata; Tomohiro Matsuo; Yuji Sagara; Kojiro Ohba; Kaname Ohyama; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2017-10-22       Impact factor: 5.923

6.  Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner.

Authors:  Bin Zhang; Xiaoting Shi; Guifang Xu; Wei Kang; Weijie Zhang; Shu Zhang; Yu Cao; Liping Qian; Ping Zhan; Hongli Yan; Ka Fai To; Lei Wang; Xiaoping Zou
Journal:  J Cell Mol Med       Date:  2017-02-12       Impact factor: 5.310

Review 7.  Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms.

Authors:  Zeina Habli; Georgio Toumieh; Maamoun Fatfat; Omar Nasser Rahal; Hala Gali-Muhtasib
Journal:  Molecules       Date:  2017-02-08       Impact factor: 4.411

8.  Piperlongumine promotes death of retinoblastoma cancer cells.

Authors:  Nathalie Allaman-Pillet; Daniel F Schorderet
Journal:  Oncotarget       Date:  2021-04-27

9.  Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway.

Authors:  Jie Zheng; Dong Ju Son; Sun Mi Gu; Ju Rang Woo; Young Wan Ham; Hee Pom Lee; Wun Jae Kim; Jae Kyung Jung; Jin Tae Hong
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

10.  Piplartine Analogues and Cytotoxic Evaluation against Glioblastoma.

Authors:  Flávio Rogério da Nóbrega; Ozlem Ozdemir; Sheila Cristina S Nascimento Sousa; Joice Nascimento Barboza; Hasan Turkez; Damião Pergentino de Sousa
Journal:  Molecules       Date:  2018-06-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.